Gossamer Bio (GOSS) Cash from Operations (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Cash from Operations of 38721000.0 for Q1 2026, up 2.52% year-over-year from 37767402.56 in Q1 2025, and up 19.86% quarter-over-quarter from 48314000.0 in Q4 2025.
Gossamer Bio (GOSS) Cash from Operations (2018 - 2026) Analysis & Trends
Gossamer Bio's Cash from Operations history runs 9 years deep, the most recent figure standing at 38721000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 2.52% year-over-year to 38721000.0; the TTM figure through Mar 2026 stood at 170263000.0 (down 1968.97% YoY), while the FY2025 annual figure was 171266000.0, down 4838.47% from the prior year.
- Cash from Operations for Q1 2026 stood at 38721000.0, up from 48314000.0 in the prior quarter.
- The five-year high for Cash from Operations was 116348000.0 in Q2 2024, with the low at 53483000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 38721000.0 (2026), against an average of 32920294.12.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 404.17% in 2024, then slumped 140.45% in 2025.
- Gossamer Bio's Cash from Operations stood at 47730000.0 in 2022, then rose by 29.97% to 33424000.0 in 2023, then decreased by 6.15% to 35481000.0 in 2024, then sank by 36.17% to 48314000.0 in 2025, then increased by 19.86% to 38721000.0 in 2026.
- Business Quant data shows GOSS's Cash from Operations at 38721000.0 in Q1 2026, 48314000.0 in Q4 2025, and 36167000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | -39.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.42 Mn |
| Jun 30, 2026 | -39.42 Mn |
| Mar 31, 2026 | -38.72 Mn |
| Mar 31, 2026 | -38.72 Mn |
| Dec 31, 2025 | -48.31 Mn |
| Dec 31, 2025 | -48.31 Mn |
| Sep 30, 2025 | -36.17 Mn |
| Sep 30, 2025 | -36.17 Mn |
| Jun 30, 2025 | -47.06 Mn |
| Jun 30, 2025 | -47.06 Mn |
| Mar 31, 2025 | -39.72 Mn |
| Mar 31, 2025 | -39.72 Mn |
| Dec 31, 2024 | -35.48 Mn |
| Dec 31, 2024 | -35.48 Mn |
| Sep 30, 2024 | -32.03 Mn |
| Sep 30, 2024 | -32.03 Mn |
| Jun 30, 2024 | 116.35 Mn |
| Jun 30, 2024 | 116.35 Mn |
| Mar 31, 2024 | -52.30 Mn |
| Mar 31, 2024 | -52.30 Mn |